July/August 2012
World Intellectual Property Review
This article discusses how pharmaceutical companies develop a winning strategy to defend their diverse portfolio of patents and the different strategies they implement. Finnegan partner James B. Monroe, speaks to claims covering chemical compounds, the difference in litigation strategies between generic and innovator companies, and the 30-month stay.
Press Release
August 19, 2026
Press Release
August 18, 2026
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.